However, alongside these generally complex evaluations, screening tools for anxiety and depression and QoL scores could be a practical and straightforward method to identify patients who are likely to remain symptomatic after CRP and who may benefit from specific MH interventions. The gene discussed is CRP; the disease is depressive symptom measurement.